Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh
Status:
Completed
Trial end date:
2015-10-14
Target enrollment:
Participant gender:
Summary
The safety and effectiveness of AmBisome 15 mg/kg, given over 15 days in 5 biweekly infusions
of 3 mg/kg on an outpatient basis, is evaluated in clinically diagnosed PKDL patients of 12
years and older in a highly endemic area in Bangladesh. This is a prospective study, with the
objective to assess final cure 12 months after treatment.